NeuroActiva™, Inc., San Jose, USA.
Adv Clin Exp Med. 2021 Jul;30(7):653-654. doi: 10.17219/acem/139501.
We don’t understand Alzheimer, its origin and disease mechanisms. The absence of disease-modifying treatments for Alzheimer today is due to the amyloid hypothesis, a misguided hypothesis of Alzheimer’s disease etiology, which has dominated Alzheimer research, drug development, and clinical trials for 30 years. However, the hypothesis is not dead yet, as exemplified by the recent resurrection of clinical trials with aducanumab. Recent advances in Alzheimer research include astrocytes, synaptic function and glutamate signaling. Many studies indicate EAAT2 as a promising target in drug discovery and clinical development for novel therapies in Alzheimer’s disease, and other neurologic and psychiatric diseases.
我们不了解阿尔茨海默病，包括其起源和疾病机制。目前缺乏能够改变阿尔茨海默病进程的治疗药物，这主要是由于 30 年来一直占主导地位的阿尔茨海默病病因学的淀粉样蛋白假说，这一假说误导了阿尔茨海默病的研究、药物研发和临床试验。然而，该假说并未完全失效，例如近期 aducanumab 的临床试验重新开展。阿尔茨海默病研究的最新进展包括星形胶质细胞、突触功能和谷氨酸信号转导。许多研究表明，EAAT2 作为一个有前途的靶点，可用于发现治疗阿尔茨海默病及其他神经和精神疾病的新药。
